Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk

Kate J Robson; A Richard Kitching

doi:10.1016/j.kint.2020.10.044

Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk

Kidney Int. 2021 Mar;99(3):545-548. doi: 10.1016/j.kint.2020.10.044.

Authors

Kate J Robson¹, A Richard Kitching²

Affiliations

¹ Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Monash University, Clayton, Victoria, Australia; Department of Nephrology, Monash Health, Clayton, Victoria, Australia.
² Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Monash University, Clayton, Victoria, Australia; Department of Nephrology, Monash Health, Clayton, Victoria, Australia; Department of Pediatric Nephrology, Monash Health, Clayton, Victoria, Australia. Electronic address: richard.kitching@monash.edu.

PMID: 33637201
DOI: 10.1016/j.kint.2020.10.044

Abstract

Membranous nephropathy, like many forms of glomerulonephritis, is an HLA-associated autoimmune disease that can recur in the transplanted kidney. In this issue of Kidney International, Berchtold and colleagues publish an intriguing and important paper on risk factors for recurrent post-transplant membranous nephropathy due to autoimmunity to PLA2R1. They found that the genetics of both the autoantigen and donor HLA are important determinants of the risk of recurrent disease in the graft.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Alleles
Glomerulonephritis*
Glomerulonephritis, Membranous* / etiology
Glomerulonephritis, Membranous* / genetics
Humans
Kidney Transplantation* / adverse effects
Receptors, Phospholipase A2
Recurrence
Tissue Donors

Substances

PLA2R1 protein, human
Receptors, Phospholipase A2